“Polpharma’s purpose is to help people live a healthy life in a healthy world. A key role in our activity is played by the development of modern pharmaceutical products that respond to contemporary health challenges, ensure drug security and expand access to effective therapies for patients in Poland and Europe. Cooperation with the EIB will help us effectively implement our long-term development plans and innovative patient-friendly solutions as well as create attractive jobs for the best specialists” – says Wojciech Rosa, Member of Polpharma S.A. Management Board.
The European Investment Bank (EIB) is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investment in order to contribute towards EU policy objectives. EIB is supporting investments in RDI that strengthen Europe’s long-term competitiveness, promote knowledge diffusion, drive economic growth and create jobs. The Innovation Loan is subject to technical viability and quality assessment by the Bank’s Projects department, which has years of broad expertise in assessing RDI programmes across a multitude of sectors and company sizes, in the EU and worldwide.